Abbott Laboratories
NYSE:ABT
Abbott Laboratories
Total Receivables
Abbott Laboratories
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$6.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Receivables
$2.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Receivables
$836.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$3.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
See Also
What is Abbott Laboratories's Total Receivables?
Total Receivables
6.6B
USD
Based on the financial report for Dec 31, 2023, Abbott Laboratories's Total Receivables amounts to 6.6B USD.
What is Abbott Laboratories's Total Receivables growth rate?
Total Receivables CAGR 10Y
5%
Over the last year, the Total Receivables growth was 6%. The average annual Total Receivables growth rates for Abbott Laboratories have been 1% over the past three years , 5% over the past five years , and 5% over the past ten years .